Formin’ a hypothesis.
That discrepant results in the oncologic impact of metformin are due to exclusive advantages among those with a high body mass index. | Arrieta, JAMA Oncol 2022
With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
That discrepant results in the oncologic impact of metformin are due to exclusive advantages among those with a high body mass index. | Arrieta, JAMA Oncol 2022
Comments
Post a Comment